We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Multicenter, prospective, double-blind, randomized, comparative, clinical study of the efficacy and tolerability of trastuzumab drugs in combination with neoadjuvant chemotherapy and subsequent adjuvant monotherapy in patients with HER2-positive operable breast cancer. Key milestones: development of the electronic CRFs; data validation; database lock.
Download the pdf document with the full results of the case study here.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
